The global companion animal health market is projected to reach USD 42.50 billion by 2030, expanding at a compound annual growth rate (CAGR) of 9.3% during the forecast period, according to a recent report by Grand View Research, Inc. The growth of this market is being primarily driven by an increase in research and development (R&D) programs, rising government initiatives, a higher rate of pet adoption, and an increase in the number of veterinary surgeries and the prevalence of chronic diseases among companion animals.

The veterinary healthcare sector, however, faced significant challenges during the COVID-19 pandemic. Despite shutdowns, veterinarians continued to work, ensuring that essential pet care services remained available. According to a survey of over 3,000 pet owners in the U.S., UK, France, and Brazil, a substantial number of pet owners, more than 25%, delayed or avoided contacting their veterinarians due to concerns over potential disease transmission during the pandemic. Despite these fears, 65% of pet owners reported that the pandemic did not significantly impact their access to medications and procedures.

A significant factor driving the companion animal health market is the increase in pet ownership. In the U.S., for example, nearly 70% of households, equating to about 90.5 million homes, own pets, with dogs and cats being the most commonly kept animals, as per the American Veterinary Medical Association. This increase in pet ownership correlates with a rising demand for pet medication and high-quality veterinary care. As more people adopt pets, they are increasingly seeking advanced veterinary services, contributing to the market's growth.

Over the past decade, veterinary research and development activities have grown significantly. Innovations in surgical techniques and specialized medications for pets have been introduced. In line with these advancements, leading market players are adopting novel technologies to maintain their competitive edge. For instance, in January 2022, the FDA approved Zoetis' monoclonal antibody treatment for osteoarthritis in cats, named Solensia, which aims to alleviate pain associated with the condition. Furthermore, the company launched Librela, a monoclonal antibody designed to reduce pain in dogs suffering from arthritis.

The rising prevalence of pet diseases, particularly in countries like France, has also been a significant factor in the growing demand for pet treatment. Common health issues affecting pets in France include obesity, dental problems, skin allergies, osteoarthritis, and viral diseases. The increase in these ailments is driving the demand for medications and preventive care to maintain pets' health and well-being. Additionally, the growing demand for pet pharmaceuticals and vaccines is expected to further boost the market.

Get a preview of the latest developments in the Companion Animal Health Market? Download your FREE sample PDF copy today and explore key data and trends. 

FAQ for the Global Companion Animal Health Market

1. What is the size of the global companion animal health market?

The global companion animal health market is expected to reach USD 42.50 billion by 2030, with a compound annual growth rate (CAGR) of 9.3% from 2024 to 2030.

2. What are the key drivers of growth in the companion animal health market?

The growth of the companion animal health market is primarily driven by rising pet ownership, increased government initiatives, advancements in veterinary healthcare, and the growing prevalence of chronic diseases in pets. Additionally, innovations in veterinary treatments and medications play a significant role in market expansion.

3. How has the COVID-19 pandemic affected the companion animal health market?

During the COVID-19 pandemic, while veterinarians continued to offer services, pet owners were hesitant to seek care due to concerns over disease transmission. However, most pet owners did not experience significant disruptions in accessing medications and treatments, and the demand for veterinary services remains strong.

4. How is the increase in pet ownership influencing the companion animal health market?

With approximately 70% of U.S. households owning pets, pet ownership is a major driver of demand for veterinary care and medications. As more people adopt pets, the market for companion animal health products, including treatments for chronic conditions, continues to grow.

5. What types of health issues are common among companion animals?

Common health issues among companion animals include obesity, dental problems, osteoarthritis, skin allergies, and viral diseases. These health concerns are driving demand for specialized medications and preventive care for pets.

6. What are the latest innovations in companion animal health treatments?

Innovations such as monoclonal antibody treatments for osteoarthritis in pets, like Zoetis' Solensia for cats and Librela for dogs, represent significant advancements in the market. These treatments aim to improve the quality of life for animals suffering from chronic conditions.

Order a free sample PDF of the Companion Animal Health Market Intelligence Study, published by Grand View Research.